Investigating bronchiectasis in patients with primary immunodeficiency in France
Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France
This study is trying to see how common bronchiectasis is in adults with primary immunodeficiency and how it affects their health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims Academic / other |
| Locations | 1 site (Reims) |
| Trial ID | NCT06355323 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the prevalence of bronchiectasis in adults with primary humoral immunodeficiency, including common variable immunodeficiency and other related conditions. It involves conducting blood tests and chest CT scans to identify the presence of bronchiectasis, which can often be asymptomatic but significantly impacts morbidity and mortality. The study seeks to establish a better understanding of the relationship between immunodeficiency and bronchiectasis, as well as to identify potential predictive factors for its development. By improving diagnosis and management, the study hopes to enhance patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adult patients diagnosed with primary humoral immunodeficiency, such as common variable immunodeficiency or IgG subclass deficiency.
Not a fit: Patients under 18 years of age or those with conditions that prevent CT scans, such as claustrophobia or obesity, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management of bronchiectasis in patients with primary immunodeficiency, potentially reducing morbidity and mortality.
How similar studies have performed: While the prevalence of bronchiectasis in primary immunodeficiency has been noted in various studies, this specific investigation into its prevalence and predictive factors is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
inclusion criteria : * Patients with primary humoral immunodeficiency defined as following : * Common variable immunodeficiency : Marked decreased in IgG seric concentration \< 5 g/L and in IgA seric concentration or IgM seric concentration (-2SD), without secondary cause * IgG subclass deficiency : marked decrease (-2SD) in at least one IgG subclass (IgG1, 2, 3 et 4) with or without IgA or IgM deficiency * Selective IgM Deficiency : isolated decrease un IgM seric concentration \<0.3g/L, without IgG or IgA deficiency * Adult patients * Patients with or without previously identified pulmonary complications * Patients agreeing to participate to the study * Patients insured under the French social security system Non-inclusion criteria : * Patients\< 18 years of age * Patients protected by law * Patients for whom CT scan is not feasible (claustrophobia, obesity...) * Pregnant women
Where this trial is running
Reims
- Damien JOLLY — Reims, France (Recruiting)
Study contacts
- Study coordinator: Amélie SERVETTAZ
- Email: aservettaz@chu-reims.fr
- Phone: 03 26 83 27 69
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.